Boston Scientific downgraded by Raymond James with a new price target
$BSX
Medical/Dental Instruments
Health Care
Raymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2026 | $88.00 | Strong Buy → Outperform | Raymond James |
| 10/3/2025 | Buy → Hold | Erste Group | |
| 9/8/2025 | $125.00 | Perform → Outperform | Oppenheimer |
| 6/16/2025 | $118.00 | Outperform | Leerink Partners |
| 4/16/2025 | $113.00 | Hold → Buy | Needham |
| 1/10/2025 | $108.00 | Hold → Buy | Deutsche Bank |
| 10/18/2024 | Buy → Hold | Needham | |
| 5/30/2024 | $90.00 | Buy | Goldman |
Raymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00
Erste Group downgraded Boston Scientific from Buy to Hold
Oppenheimer upgraded Boston Scientific from Perform to Outperform and set a new price target of $125.00
MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation aloneLate breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating tha
S-4/A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
SCHEDULE 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide
COPENHAGEN, Denmark, Dec. 10, 2025 /PRNewswire/ -- CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. Eric Thepaut Appointed Independent Chairman of the Board Eric Thepaut joins CathVision following his recent retirement from Boston Scientific Corporation (NYSE:BSX), where he serv
BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the potential of this exciting project and providing the funding to facilitate execution of
Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son
MARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev
ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter
MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
SC 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)